# Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

> **NCT01057225** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 64 (actual)

## Conditions studied

- Multiple Myeloma
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **DRUG:** carfilzomib
- **DRUG:** cyclophosphamide
- **DRUG:** thalidomide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT01057225
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2014-03
- **Final completion:** 2017-09-05
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2017-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01057225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01057225, "Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01057225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*